Cui Miao, Deng Fei, Disis Mary L, Cheng Chao, Zhang Lanjing
Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Pathology, Mount Sinai West, New York, NY, USA.
Explor Res Hypothesis Med. 2024 Jul-Sep;9(3):209-220. doi: 10.14218/erhm.2024.00006. Epub 2024 Jul 3.
High-throughput proteomics has become an exciting field and a potential frontier of modern medicine since the early 2000s. While significant progress has been made in the technical aspects of the field, translating proteomics to clinical applications has been challenging. This review summarizes recent advances in clinical applications of high-throughput proteomics and discusses the associated challenges, advantages, and future directions. We focus on research progress and clinical applications of high-throughput proteomics in breast cancer, bladder cancer, laryngeal squamous cell carcinoma, gastric cancer, colorectal cancer, and coronavirus disease 2019. The future application of high-throughput proteomics will face challenges such as varying protein properties, limitations of statistical modeling, technical and logistical difficulties in data deposition, integration, and harmonization, as well as regulatory requirements for clinical validation and considerations. However, there are several noteworthy advantages of high-throughput proteomics, including the identification of novel global protein networks, the discovery of new proteins, and the synergistic incorporation with other omic data. We look forward to participating in and embracing future advances in high-throughput proteomics, such as proteomics-based single-cell biology and its clinical applications, individualized proteomics, pathology informatics, digital pathology, and deep learning models for high-throughput proteomics. Several new proteomic technologies are noteworthy, including data-independent acquisition mass spectrometry, nanopore-based proteomics, 4-D proteomics, and secondary ion mass spectrometry. In summary, we believe high-throughput proteomics will drastically shift the paradigm of translational research, clinical practice, and public health in the near future.
自21世纪初以来，高通量蛋白质组学已成为一个令人兴奋的领域和现代医学的潜在前沿。虽然该领域在技术方面取得了重大进展，但将蛋白质组学转化为临床应用一直具有挑战性。本综述总结了高通量蛋白质组学临床应用的最新进展，并讨论了相关的挑战、优势和未来方向。我们重点关注高通量蛋白质组学在乳腺癌、膀胱癌、喉鳞状细胞癌、胃癌、结直肠癌和2019冠状病毒病中的研究进展和临床应用。高通量蛋白质组学的未来应用将面临各种挑战，如蛋白质特性各异、统计建模的局限性、数据存储、整合和协调方面的技术和后勤困难，以及临床验证和考量的监管要求。然而，高通量蛋白质组学有几个值得注意的优点，包括识别新的全局蛋白质网络、发现新蛋白质以及与其他组学数据的协同整合。我们期待参与并迎接高通量蛋白质组学的未来进展，如基于蛋白质组学的单细胞生物学及其临床应用、个性化蛋白质组学、病理学信息学、数字病理学以及高通量蛋白质组学的深度学习模型。几种新的蛋白质组学技术值得关注，包括数据非依赖采集质谱、基于纳米孔的蛋白质组学、4-D蛋白质组学和二次离子质谱。总之，我们相信高通量蛋白质组学将在不久的将来极大地改变转化研究、临床实践和公共卫生的范式。
